Overview Dividends

(ALGN) Align Technology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0162551016

Clear Aligners, Retainers, Intraoral Scanners, CAD/CAM Software

ALGN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 16.13%
EPS Trend (3Y Correlation): 78.1%

ALGN Revenue

Revenue Growth (3Y CAGR): 3.68%
Revenue Trend (3Y Correlation): 64.9%

Risk via 10d forecast
Volatility	42.0%
Value at Risk 5%th	62.3%

Reward
Sharpe Ratio	-0.57
Alpha	-59.39

Character
Hurst Exponent	0.228
Beta	1.704

Drawdowns 3y
Max DD	67.59%
Mean DD	33.15%

Description: ALGN Align Technology October 30, 2025

Align Technology (NASDAQ:ALGN) designs, manufactures, and markets the Invisalign clear-aligner system, Vivera retainers, and iTero intra-oral scanners, serving dental professionals in the United States, Switzerland, and other international markets.

The Clear Aligner segment bundles Invisalign treatments for adults, teens, and younger children (ages 6-10) through products such as Invisalign First, Invisalign Express, Lite, Moderate, and the Go line, plus ancillary tools like whitening kits, palatal expanders, and 3-D-printed orthodontic devices.

The Imaging Systems & CAD/CAM Services segment centers on the iTero scanner platform, paired with exocad design software, digital record-keeping tools, outcome simulators, and subscription-based services (e.g., pay-per-scan, scanner rentals) that support both orthodontic and restorative workflows.

Key metrics: FY 2024 revenue reached $4.9 billion, up ~13 % YoY, driven by a ~22 % increase in Invisalign case volume and a ~15 % rise in iTero scanner subscriptions. The global clear-aligner market is projected to grow at a 10-12 % CAGR through 2029, fueled by rising consumer preference for aesthetic, low-pain orthodontics and expanding dental insurance coverage for digital treatments.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of ALGN’s valuation multiples and scenario analyses.

ALGN Stock Overview

Market Cap in USD	10,034m
Sub-Industry	Health Care Supplies
IPO / Inception	2001-01-26
Return 12m vs S&P 500	-44.4%
Analyst Rating	4.0 of 5

ALGN Dividends

Currently no dividends paid

ALGN Growth Ratios

CAGR	-12.23%
CAGR/Max DD Calmar Ratio	-0.18
CAGR/Mean DD Pain Ratio	-0.37
Current Volume	1427.8k
Average Volume	1075.9k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (378.4m TTM) > 0 and > 6% of Revenue (6% = 239.0m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 4.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 14.25% (prev 13.48%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 656.1m > Net Income 378.4m (YES >=105%, WARN >=100%)

Net Debt (-917.3m) to EBITDA (689.6m) ratio: -1.33 <= 3.0 (WARN <= 3.5)

Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (72.4m) change vs 12m ago -3.13% (target <= -2.0% for YES)

Gross Margin 68.41% (prev 69.98%; Δ -1.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 63.22% (prev 62.21%; Δ 1.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 304.0 (EBITDA TTM 689.6m / Interest Expense TTM 1.56m) >= 6 (WARN >= 3)

Altman Z'' 3.55

(A) 0.09 = (Total Current Assets 2.53b - Total Current Liabilities 1.97b) / Total Assets 6.23b

(B) 0.40 = Retained Earnings (Balance) 2.48b / Total Assets 6.23b

(D) 1.09 = Book Value of Equity 2.49b / Total Liabilities 2.28b

Total Rating: 3.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.03

1. Piotroski 7.0pt = 2.0

2. FCF Yield 6.94% = 3.47

3. FCF Margin 15.90% = 3.97

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -1.33 = 2.50

6. ROIC - WACC (= -4.80)% = -6.00

7. RoE 9.75% = 0.81

8. Rev. Trend 64.93% = 4.87

9. EPS Trend 78.12% = 3.91

What is the price of ALGN shares?

As of November 12, 2025, the stock is trading at USD 144.49 with a total of 1,427,754 shares traded.
Over the past week, the price has changed by +6.50%, over one month by +11.54%, over three months by +7.17% and over the past year by -35.85%.

Is Align Technology a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Align Technology (NASDAQ:ALGN) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.03 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALGN is around 107.88 USD . This means that ALGN is currently overvalued and has a potential downside of -25.34%.

Is ALGN a buy, sell or hold?

Align Technology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALGN.

Strong Buy: 8
Buy: 3
Hold: 6
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the ALGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	179.1	23.9%
Analysts Target Price	179.1	23.9%
ValueRay Target Price	124.3	-14%

ALGN Fundamental Data Overview November 01, 2025

Market Cap USD = 10.03b (10.03b USD * 1.0 USD.USD)
P/E Trailing = 26.8275
P/E Forward = 11.976
P/S = 2.5308
P/B = 2.3842
P/EG = 0.7631
Beta = 1.704
Revenue TTM = 3.98b USD
EBIT TTM = 475.4m USD
EBITDA TTM = 689.6m USD
Long Term Debt = 119.3m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 62.1m USD (from shortTermDebt, last fiscal year)
Debt = 87.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -917.3m USD (from netDebt column, last quarter)
Enterprise Value = 9.12b USD (10.03b + Debt 87.3m - CCE 1.00b)
Interest Coverage Ratio = 304.0 (Ebit TTM 475.4m / Interest Expense TTM 1.56m)
FCF Yield = 6.94% (FCF TTM 633.2m / Enterprise Value 9.12b)
FCF Margin = 15.90% (FCF TTM 633.2m / Revenue TTM 3.98b)
Net Margin = 9.50% (Net Income TTM 378.4m / Revenue TTM 3.98b)
Gross Margin = 68.41% ((Revenue TTM 3.98b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.20% (prev 69.94%)
Tobins Q-Ratio = 1.46 (Enterprise Value 9.12b / Total Assets 6.23b)
Interest Expense / Debt = 1.79% (Interest Expense 1.56m / Debt 87.3m)
Taxrate = 40.09% (38.0m / 94.7m)
NOPAT = 284.8m (EBIT 475.4m * (1 - 40.09%))
Current Ratio = 1.29 (Total Current Assets 2.53b / Total Current Liabilities 1.97b)
Debt / Equity = 0.02 (Debt 87.3m / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = -1.33 (Net Debt -917.3m / EBITDA 689.6m)
Debt / FCF = -1.45 (Net Debt -917.3m / FCF TTM 633.2m)
Total Stockholder Equity = 3.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 378.4m / Total Assets 6.23b)
RoE = 9.75% (Net Income TTM 378.4m / Total Stockholder Equity 3.88b)
RoCE = 11.89% (EBIT 475.4m / Capital Employed (Equity 3.88b + L.T.Debt 119.3m))
RoIC = 7.39% (NOPAT 284.8m / Invested Capital 3.85b)
WACC = 12.19% (E(10.03b)/V(10.12b) * Re(12.29%) + D(87.3m)/V(10.12b) * Rd(1.79%) * (1-Tc(0.40)))
Discount Rate = 12.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.26%
[DCF Debug] Terminal Value 66.92% ; FCFE base≈529.1m ; Y1≈603.9m ; Y5≈834.8m
Fair Price DCF = 106.9 (DCF Value 7.75b / Shares Outstanding 72.5m; 5y FCF grow 16.51% → 3.0% )
EPS Correlation: 78.12 | EPS CAGR: 16.13% | SUE: 1.67 | # QB: 1
Revenue Correlation: 64.93 | Revenue CAGR: 3.68% | SUE: 0.56 | # QB: 0

Additional Sources for ALGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle